GlassScriptPhysician profile
Ronald J Estes
NPI 1366487449
$13,692.27
in general payments reported to CMS, 2019-2025
44 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,106 · 2020: $741 · 2021: $1,081 · 2022: $2,260 · 2023: $2,506 · 2024: $1,771 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,453 · Education: $50.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,452.73 |
| Education | $50.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,015.24 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,019.10 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,115.43 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Ethicon INC. | $915.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $850.91 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Amgen INC. | $760.45 | 2022-2025 | Tezspire, Tavneos |
| Insmed, INC. | $678.21 | 2019-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $558.64 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $462.00 | 2021-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $388.50 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $365.64 | 2024-2025 | Dupixent |
| Intuitive Surgical, INC. | $319.67 | 2022-2023 | Da Vinci Surgical System |
| Mylan Specialty L.P. | $222.54 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $201.14 | 2021-2024 | Glassia |
| Genentech USA, INC. | $177.19 | 2019-2023 | Xolair |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $155.50 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $146.10 | 2019-2023 | |
| Galvanize Therapeutics, INC | $115.58 | 2025 | Aliya System |
| Merck Sharp & Dohme LLC | $109.28 | 2019-2025 | Winrevair, Keytruda |
| Advanced Respiratory, INC | $107.41 | 2019-2021 | |
| Ucb, INC. | $99.98 | 2023 | Briviact |
| Viatris Specialty LLC | $91.46 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $88.83 | 2024-2025 | Acthar |
| Cumberland Pharmaceuticals, INC. | $82.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.69 | 2021-2023 | |
| Gilead Sciences, INC. | $62.81 | 2019-2023 | Veklury |
| Pfizer INC. | $57.22 | 2021-2024 | |
| Circassia INC. | $44.06 | 2019 | |
| Mallinckrodt Enterprises LLC | $42.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $42.34 | 2019-2020 | |
| Olympus America INC. | $39.55 | 2022 | |
| Electromed, INC. | $36.14 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $29.21 | 2019 | |
| Shire North American Group INC | $29.15 | 2019 | |
| Optinose US, INC. | $27.72 | 2024 | |
| Allergan, INC. | $24.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.97 | 2020-2022 | |
| Ani Pharmaceuticals, INC. | $21.03 | 2023 | Purified Cortrophin Gel |
| Pulmonx Corporation | $20.03 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Verona Pharma, INC. | $18.51 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $18.08 | 2025 | Giapreza |
| Harmony Biosciences LLC | $16.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.45 | 2022 | |
| Inogen, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.